Bicycle Therapeutics plc

NasdaqGS:BCYC Stock Report

Market Cap: US$1.0b

Bicycle Therapeutics Future Growth

Future criteria checks 2/6

Bicycle Therapeutics is forecast to grow earnings and revenue by 4.1% and 51% per annum respectively. EPS is expected to grow by 11.1% per annum. Return on equity is forecast to be -157.1% in 3 years.

Key information

4.1%

Earnings growth rate

11.1%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate51.0%
Future return on equity-157.1%
Analyst coverage

Good

Last updated23 Feb 2024

Recent future growth updates

Recent updates

Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point

Mar 12

Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Jan 04
Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely

Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

Nov 07
Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts

The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

May 14
The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts

Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Mar 31
Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%

Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Mar 09
Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?

Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Nov 08
Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook

Bicycle Therapeutics: Exploring An Intriguing Developmental Platform

Oct 08

Bicycle Therapeutics initiated Outperform at Cowen citing drug platform

Aug 31

Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration

Jul 12

Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Jul 10
Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?

Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer

Jul 05

Bicycle Therapeutics: Trying To Catch This Falling Knife

Apr 17

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Apr 11
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Bicycle Therapeutics: A Buy Ahead Of AACR Presentation

Mar 25

Bicycle Therapeutics: An Oncology Play With Big Potential

Feb 28

Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Nov 07
Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?

Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles

Aug 25

The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

Aug 07
The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically

News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

May 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts

Bicycle Therapeutics EPS misses by $0.05, beats on revenue

May 06

Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Mar 08
Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates

Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Feb 23
Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?

Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

Jan 19
Announcing: Bicycle Therapeutics (NASDAQ:BCYC) Stock Increased An Energizing 141% In The Last Year

Bicycle Therapeutics gives out pipeline update, shares rise

Jan 14

What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Dec 15
What Type Of Shareholders Own The Most Number of Bicycle Therapeutics plc (NASDAQ:BCYC) Shares?

Bicycle Therapeutics settles IP dispute with Pepscan

Nov 30

Earnings and Revenue Growth Forecasts

NasdaqGS:BCYC - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202646-284-263-18210
12/31/202527-261-255-16912
12/31/202428-227-211-17313
12/31/202327-181-64-61N/A
9/30/202325-162-48-44N/A
6/30/202323-140-55-48N/A
3/31/202315-124-122-106N/A
12/31/202214-113-105-86N/A
9/30/202215-101-85-66N/A
6/30/202216-87-54-39N/A
3/31/202214-78-34-27N/A
12/31/202112-67-17-15N/A
9/30/202112-66-22-21N/A
6/30/202111-62-54-53N/A
3/31/202111-56-54-53N/A
12/31/202010-51-19-18N/A
9/30/202012-38-7-6N/A
6/30/20209-37-8-7N/A
3/31/20209-35-4-2N/A
12/31/201914-31-30-29N/A
9/30/201910-33-34-33N/A
6/30/201911-31-28-26N/A
3/31/201911-26-25-24N/A
12/31/20187-22-27-26N/A
9/30/20187-21-20-19N/A
12/31/20172-16-3-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCYC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCYC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCYC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCYC's revenue (51% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: BCYC's revenue (51% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BCYC is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.